Charles River's Q4 Earnings Beats Street Expectation, Reaffirms FY22 Outlook


Charles River Laboratories International Inc's CRL Q4 sales increased 14.4% Y/Y to $905.1 million, beating the consensus of $888.27 million.

  • Acquisitions contributed 5.9% to consolidated fourth-quarter revenue growth. Organic revenue growth was 10.5%, driven by contributions from all three business segments. 
  • Adjusted EPS reached $2.49 higher than $2.39 posted a year ago and better than the consensus of $2.43.
  • Revenue for the Research Models and Services (RMS)segment was $165.6 million, +5.7%. Organic revenue growth of 13.3% was primarily driven by robust demand for research models & related services.
  • Discovery and Safety Assessment sales increased 7.9% to $534.1 million. Organically sales increased 6.7%, driven principally by the Safety Assessment business, with the Discovery Services business also contributing.
  • The manufacturing segment sales were $205.3 million, up 47.4% from $139.3 million. The acquisitions of Cognate BioServices and Vigene Biosciences contributed 27.8% to Manufacturing revenue growth.
  • Guidance: Charles River reaffirmed FY22 guidance with 13-15% sales growth and organic growth of 12.5% – 14.5%.
  • The Company expects adjusted EPS of $11.50 – $11.75, compared to the consensus of $11.59.
  • Price Action: CRL shares traded 3.01% lower at $303.24 on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsGuidanceHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!